The Zacks: Analysts Anticipate Gilead Sciences, Inc. (GILD) Will Announce Earnings of $2.04 Per Share

The Zacks: Analysts Anticipate Gilead Sciences, Inc. (GILD) Will Announce Earnings of $2.04 Per Share

On average, analysts expect that Gilead Sciences will report full year earnings of $7.88 per share for the current fiscal year, with EPS estimates ranging from $6.86 to $8.31. For the next year, analysts anticipate that the company will report earnings of $7.41 per share, with EPS estimates ranging from $6.26 to $8.46. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Gilead Sciences.

Wall Street brokerages predict that Gilead Sciences, Inc. (NASDAQ:GILD) will report $2.04 earnings per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Gilead Sciences’ earnings. The highest EPS estimate is $2.17 and the lowest is $1.87. Gilead Sciences reported earnings per share of $3.03 during the same quarter last year, which suggests a negative year-over-year growth rate of 32.7%. The business is expected to issue its next quarterly earnings results on Monday, July 24th.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The company earned $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Several analysts have recently weighed in on the company. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $76.06 target price for the company in a report on Wednesday. Barclays PLC reissued an “overweight” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Wednesday. Credit Suisse Group AG reissued an “outperform” rating and issued a $79.00 target price on shares of Gilead Sciences in a report on Friday. Gabelli reissued a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Wednesday. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Eleven analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $80.67.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The company earned $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $214,973,917.42. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $67.48, for a total value of $337,400.00. Following the sale, the executive vice president now owns 117,988 shares in the company, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in GILD. Sullivan Bruyette Speros & Blaney LLC boosted its stake in shares of Gilead Sciences by 0.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 6,779 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 42 shares during the period. Bluestein R H & Co. boosted its stake in shares of Gilead Sciences by 1.2% in the fourth quarter. Bluestein R H & Co. now owns 3,665 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 45 shares during the period. Brown Brothers Harriman & Co. boosted its stake in shares of Gilead Sciences by 0.9% in the third quarter. Brown Brothers Harriman & Co. now owns 5,117 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 46 shares during the period. Abner Herrman & Brock LLC boosted its stake in shares of Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the period. Finally, HighPoint Advisor Group LLC boosted its stake in shares of Gilead Sciences by 0.5% in the third quarter. HighPoint Advisor Group LLC now owns 11,074 shares of the biopharmaceutical company’s stock worth $837,000 after buying an additional 51 shares during the period. Hedge funds and other institutional investors own 74.19% of the company’s stock. Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.41% on Monday, hitting $67.80. The stock had a trading volume of 5,788,814 shares. The firm’s 50-day moving average price is $67.27 and its 200 day moving average price is $71.20. The firm has a market cap of $88.62 billion, a PE ratio of 6.82 and a beta of 1.11. Gilead Sciences has a 52-week low of $65.38 and a 52-week high of $88.85.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Friday, June 16th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 18.91%. Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Gilead Sciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment